M3 is strengthening and growing its global operations with the acquisition of iDoctus, a trusted provider of prescribing information and clinical decision support services to doctors in Spain, Mexico and rest of Latin America. This move strengthens M3’s existing activities in the region, as well as complements M3’s global footprint.
iDoctus is a Madrid based company and provides the market leading point-of-care mobile app “iDoctus” for physicians in the Spanish language. iDoctus’ mission is to provide physicians with an easy to use, up to date, and accurate prescription decision support and clinical reference app for physicians to support better patient care. Its platform provides drug reference information, relevant scientific and clinical updates and disease-specific point-of-care tools such as interaction checkers, dosing calculators and medical scores.
Since its launch in 2011, iDoctus has become one of the most widely used apps for doctors in Spain, Mexico and rest of Latin America, with localized content in 19 countries. iDoctus has approximately 500,000 physician members1. Combined with M3’s existing position in Vademecum, M3 will be used by over 80% of Spanish physicians.
Aki Tomaru, Board Director of M3, commented: “The addition of iDoctus marks a very significant and important step for M3 in its mission to deliver trusted, useful medical information and services across the world. iDoctus’ app-first capability and strong physician user base provides us with an exceptional platform to drive forward innovation, improved efficiency and better outcomes in healthcare in these markets”.
“We are thrilled for iDoctus to join forces with M3, the global market leader in digital healthcare. The combination of global scale and broad portfolio of services and competencies of M3 with the services and mobile focus of iDoctus will help us accelerate the development of innovative digital HCP solutions within our footprint and beyond”, commented Angel Diaz Alegre, CEO of iDoctus.
Baker McKenzie´s Corporate/M&A team was formed by partner and head of the Practice Group Javier Menor, Corporate M&A special counsel Alba Anegón, associate Pablo García and junior Isabel Rodríguez.
